Sienna Miller, 44, has announced that she is expecting her third child, a development that has sparked discussions about age-related criticism in parenting. Miller shared the news on social media after an eight-month hiatus, highlighting her journey as a mother.

Currently, Miller has a two-year-old daughter with her boyfriend, Oli Green, and a 13-year-old daughter with her ex-partner, Tom Sturridge. She expressed that being pregnant in her 40s has been a more rewarding experience compared to her 20s, stating, “Having had a baby at 29, and then having a baby at 42, and now 44, it’s so much easier when you don’t have the conflict of feeling scattered and like you want to be doing X, Y, Z.”

Miller’s perspective on motherhood has evolved significantly over the years. She believes that by the time women reach 40, they possess a clearer understanding of themselves and are less concerned about others’ opinions. “I kind of know who I am. I don’t really give a s*** about what anyone else thinks,” she remarked.

Despite the societal scrutiny surrounding older motherhood, Miller challenges the narrative by questioning why men are not judged similarly. “We don’t judge men who are having kids in their 80s. Why on earth is there any sort of narrative?” she stated, emphasizing the double standards in societal expectations.

Miller’s journey to motherhood has not been without its challenges. She froze her eggs in her late 30s but ultimately did not use them. Reflecting on her experiences, she noted, “I was really fortunately able just to get pregnant, but it was an existential relief having done that in my late 30s.”

Her recent pregnancy news comes on the heels of her acclaimed performance in the film ‘Horizon: An American Saga,’ where her portrayal was praised for its depth and authenticity.

As Miller prepares for this new chapter in her life, her candid discussions about age and motherhood resonate with many, challenging stereotypes and encouraging a more inclusive dialogue about parenting at any age.

The post Sienna Miller Expecting Third Child at 44 Amid Age-Related Criticism appeared first on cottenhamnews.

Veoza (fezolinetant) has been officially approved for use on the National Health Service (NHS) in England, providing a new option for menopausal women suffering from hot flushes. This treatment is particularly significant as it is aimed at the approximately 500,000 women in England who are unable to use hormone replacement therapy (HRT).

Impact of Hot Flushes

Hot flushes affect around 70% of women experiencing menopause, often leading to significant discomfort and impacting their quality of life. Helen Knight, a representative from the National Institute for Health and Care Excellence (NICE), stated, “We know that menopausal hot flushes and night sweats can have a profound impact on quality of life and significantly affect overall wellbeing.” This highlights the urgent need for effective treatments.

How Veoza Works

Veoza is designed to be taken as a once-daily oral tablet. It operates by blocking nerve pathways in the brain that trigger hot flushes and night sweats, offering a non-hormonal alternative for those who cannot or prefer not to take HRT. Dr. Sue Mann, a menopause specialist, remarked, “Symptoms of menopause including hot flushes and night sweats can affect every part of a woman’s life, so this is very welcome news especially for women who are unable to or don’t wish to take hormone replacement therapy.”

Cost and Accessibility

The NHS has set the list price for Veoza at £44.80 for a 28-tablet pack. NICE has evaluated the drug and found it to be cost-effective, indicating that it offers value for the taxpayer while addressing a critical health issue for many women. This approval is expected to ease the burden on healthcare providers by providing a viable treatment option.

For decades, there have been few safe and effective treatment options available for menopausal hot flushes, leaving many women to suffer in silence. The introduction of Veoza marks a significant advancement in the management of menopause symptoms, particularly for those who have had limited options in the past.

Future Expectations

With the approval of Veoza, healthcare professionals and advocates are optimistic about the potential relief it can provide to many women experiencing menopause. Dr. Sue Mann added, “It’s another vital treatment option which could help hundreds of thousands of women experiencing menopause to better manage their symptoms and feel more in control of their health.” As the drug becomes available, it will be crucial to monitor its uptake and effectiveness in real-world settings.

Details remain unconfirmed regarding the broader implications of Veoza’s approval on the healthcare system and its long-term effects on women’s health. However, the initial response from the medical community suggests a positive outlook for those seeking relief from menopausal symptoms.

The post Veoza Approved for Menopause Treatment in England appeared first on cottenhamnews.

Veoza (fezolinetant) has been officially approved for use on the National Health Service (NHS) in England, marking a significant advancement in the treatment options available for menopausal women suffering from hot flushes. This new oral medication is particularly aimed at women for whom hormone replacement therapy (HRT) is unsuitable, providing a much-needed alternative in managing menopausal symptoms.

Hot flushes affect approximately 70% of women during menopause, causing discomfort and impacting their quality of life. With around 500,000 women in England expected to benefit from this treatment, the approval of Veoza is seen as a crucial development in women’s health.

How Veoza Works

Veoza is designed as a once-daily oral tablet that operates by blocking nerve pathways in the brain responsible for triggering hot flushes and night sweats. This mechanism offers a new approach to alleviating symptoms that have long been a challenge for many women. Helen Knight, a representative from NICE, emphasized the importance of this treatment, stating, “We know that menopausal hot flushes and night sweats can have a profound impact on quality of life and significantly affect overall wellbeing.”

The NHS has set the list price for Veoza at £44.80 per 28-tablet pack. NICE has determined that fezolinetant is cost-effective and provides value for taxpayers, which is a positive indication for its widespread adoption within the healthcare system.

Expert Opinions on the Approval

Healthcare professionals have welcomed the approval of Veoza, highlighting its potential to improve the lives of many women. Dr. Sue Mann remarked, “Symptoms of menopause including hot flushes and night sweats can affect every part of a woman’s life, so this is very welcome news especially for women who are unable to or don’t wish to take hormone replacement therapy.” This sentiment underscores the significance of having diverse treatment options available.

Furthermore, Knight noted, “This decision will give much-needed relief to those for whom HRT is unsuitable,” reinforcing the drug’s role in addressing the needs of a specific patient demographic. The approval of Veoza is particularly timely, as for decades, there have been few safe and effective treatment options for menopausal hot flushes.

Future Implications

As Veoza becomes available, healthcare providers are optimistic about its impact on managing menopausal symptoms. It represents another vital treatment option that could help hundreds of thousands of women better manage their symptoms and feel more in control of their health. Observers are keen to see how this new treatment will be integrated into existing healthcare practices and what feedback will emerge from patients using Veoza.

Details remain unconfirmed regarding the long-term effects of the drug and its acceptance among healthcare providers. However, the initial response to Veoza’s approval has been overwhelmingly positive, suggesting a promising future for women’s health in managing menopause-related symptoms.

The post Veoza Approved for Menopause Treatment in England appeared first on cottenhamnews.